Featured Research

from universities, journals, and other organizations

Retroviral Protein Triggers Proliferation Of Immune Cells

Date:
October 23, 2003
Source:
Ohio State University
Summary:
Scientists here have found that a protein in the retrovirus known as human T-cell lymphotropic virus type 1 (HTLV-1) can cause immune cells to divide and proliferate, helping the virus spread through the body.

Columbus, Ohio – Scientists here have found that a protein in the retrovirus known as human T-cell lymphotropic virus type 1 (HTLV-1) can cause immune cells to divide and proliferate, helping the virus spread through the body.

The protein, known as p12, was formerly thought to be unimportant during infection, causing scientists to regard it as a nonessential "accessory gene."

This new study, however, shows that the protein forces infected cells to produce interleukin 2 (IL-2), a substance that stimulates the growth and proliferation of immune cells known as T lymphocytes, or T cells, which are the virus's chief target. The study was published in the Oct. 15 issue of the Journal of Virology.

"Our findings help explain why lymphocytes divide and proliferate in people following HTLV-1 infection," says lead investigator Michael D. Lairmore, professor and chair of veterinary biosciences, professor of molecular virology and associate director for basic sciences at the Ohio State University Comprehensive Cancer Center. "The findings also support the view that this virus replicates mainly by causing infected cells to divide and proliferate rather than by generating more virus particles."

The study provides insight into the biology of HTLV-1 and the changes lymphocytes undergo as they become cancerous. The findings also may lead to safer, more effective drugs to treat the leukemias, lymphoma, and autoimmune-like diseases caused by the virus.

HTLV-1 infects 15 to 25 million people worldwide, particularly in Japan and in the Caribbean region. It specifically attacks immune cells known as CD4 lymphocytes, where it inserts its genome, or genetic material, permanently into a chromosome. In some people the virus causes adult T-cell leukemia/lymphoma, a cancer that responds poorly to treatment and that can cause death within six months of diagnosis. In others, it causes crippling and painful autoimmune-like disorders.

Lairmore and a team of colleagues tested the function of p12 in both laboratory-grown lymphocytes known as Jurkat T cells, and in normal human T lymphocytes, known as peripheral blood mononuclear lymphocytes (PBMCs). Jurkat cells are commonly used for immunological studies, while PBMCs contain HTLV-1's normal target cell.

Copies of the p12 gene were transferred into both cell types. Then the genes were activated as they would be during HTLV-1 infection, causing the cells to produce p12 and IL-2. After several days, the cultured cells produced twice the level of IL-2 compared to control cells, and the normal lymphocytes produced levels six-fold higher than controls.

"A similar two-to-six fold increase in IL-2 production by infected T cells during normal HTLV-1 infection in the body would lead to a significant increase in lymphocyte numbers in the blood," says Lairmore.

"Overall, our evidence suggests that this protein plays a vital role in early HTLV-1 infection."


Story Source:

The above story is based on materials provided by Ohio State University. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University. "Retroviral Protein Triggers Proliferation Of Immune Cells." ScienceDaily. ScienceDaily, 23 October 2003. <www.sciencedaily.com/releases/2003/10/031023070706.htm>.
Ohio State University. (2003, October 23). Retroviral Protein Triggers Proliferation Of Immune Cells. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2003/10/031023070706.htm
Ohio State University. "Retroviral Protein Triggers Proliferation Of Immune Cells." ScienceDaily. www.sciencedaily.com/releases/2003/10/031023070706.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins